Education
About Us
Working with TipRanks
Follow Us
arGEN-X SE (GB:0QW0)
LSE:0QW0
Earnings Data
Report Date
Feb 26, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
5.27Last Year’s EPS
11.32Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance, significant product adoption, and promising pipeline progress, overshadowing the challenges faced in specific areas such as dermatomyositis and lupus nephritis studies.Company Guidance
Record-Breaking Revenue Achievement
Argenx reported total product net sales of $1.13 billion in Q3 2025, surpassing $1 billion in VYVGART sales in a single quarter for the first time. This represents a growth of 19% from the previous quarter and 96% year-over-year.
Successful Launch and Adoption of Prefilled Syringe
The prefilled syringe (PFS) is driving increased VYVGART demand, with more than half of new users being new to VYVGART. It has expanded the prescriber base significantly, with 260 new prescribers.
Pipeline and Regulatory Progress
Argenx will enter 2026 with 3 Phase III assets, including efgartigimod, empasiprubart, and ARGX-119. The company is on track for 5 registrational readouts next year.
Positive Data in Clinical Trials
The ADAPT subcu study showed that up to 60% of patients reached minimum symptom expression (MSE) with 83% maintaining it for at least 8 weeks. Additionally, significant improvements were observed in MG-ADL scores in the ADAPT SERON study.
Strong Financial Position
Argenx's cash balance stood at $4.3 billion, representing nearly a $1 billion increase since the beginning of the year.
GB:0QW0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0QW0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | €720.77 | €723.71 | +0.41% |
Jul 31, 2025 | €518.28 | €593.70 | +14.55% |
May 08, 2025 | €549.35 | €488.35 | -11.10% |
Feb 27, 2025 | €598.91 | €609.95 | +1.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does arGEN-X SE (GB:0QW0) report earnings?
arGEN-X SE (GB:0QW0) is schdueled to report earning on Feb 26, 2026, TBA (Confirmed).
What is arGEN-X SE (GB:0QW0) earnings time?
arGEN-X SE (GB:0QW0) earnings time is at Feb 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of arGEN-X SE stock?
The P/E ratio of arGEN X is N/A.
What is GB:0QW0 EPS forecast?
GB:0QW0 EPS forecast for the fiscal quarter 2025 (Q4) is 5.27.